A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

Teri N. Kreisl, Weiting Zhang, Yazmin Odia, Joanna H. Shih, John A. Butman, Dima Hammoud, Fabio M. Iwamoto, Joohee Sul, Howard A. Fine

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated every 4 weeks. Correlative dynamic contrast-enhanced MR and 18fluorodeoxyglucose PET imaging studies were obtained to evaluate physiologic changes in tumor and tumor vasculature at time points including baseline, 96 h after the first dose, and after the first 4 weeks of therapy. Median overall survival was 12 months (95% confidence interval [CI]: 6.08-22.8). Median progression-free survival was 2.93 months (95% CI: 2.01-4.93), and 6-month progression-free survival was 20.9% (95% CI: 10.3%-42.5%). Thirteen (43%) patients achieved a partial response. The most common grade ≥3 treatment-related toxicities were hypertension, hypophosphatemia, and thromboembolism. Singleagent bevacizumab produces significant radiographic response in patients with recurrent anaplastic glioma but did not meet the 6-month progression-free survival endpoint. Early change in enhancing tumor volume at 4 days after start of therapy was the most significant prognostic factor for overall and progression-free survival.

Original languageEnglish (US)
Pages (from-to)1143-1150
Number of pages8
JournalNeuro-oncology
Volume13
Issue number10
DOIs
StatePublished - Oct 2011

Keywords

  • Anaplastic glioma
  • Bevacizumab
  • FDG
  • Perfusion MRI

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma'. Together they form a unique fingerprint.

Cite this